Biogen Executive Director-Head of New Portfolio, Intercontinental in Cambridge, Massachusetts
The Head of New Portfolio Biogen Intercontinental Region is the overall cross functional, Lead of Biogen’s upcoming pipeline outside of MS, SMA and Alzheimer’s in the Intercontinental region. This includes all affiliates across LATAM, APAC, Japan, MART, and all associated partner markets within the region.
This position is responsible for our current Pipeline business and all upcoming launch planning of new assets currently with our Global PDC teams working on therapeutic areas including Lupus, Ophthalmology, Stroke and Pain, seamless strategy execution, sharing best practices across all functions and countries and actively support global strategy definition and giving input on behalf of Biogen Intercontinental Team. It is the main point of contact with the global PDC teams (Product Development & Commercialization) and is working closely with all countries to develop the BIR launch plans, acceleration / executional plans and defines and tracks key performance indicators. This position is reporting directly to the President of the region and is a member of the Biogen Leaderhip Team.
This New Portfolio BIR Lead position assumes responsibility to provide and leverage support, expertise and resources to local affiliates and provide direct assistance and services to management. The scope of the role comprises:
Lead cross functional BIR New Portfolio team – matrix organization
Executional excellence & performance tracking – in close collaboration and co creation with the countries, in the spirit of SERVING the countries and adding value – without “review mentality” – 50:50 principle – to support them with substance and work with them on their execution strategy and quality
Proactively share insights from other countries e.g. US to learn from their experience and insights including data on performance etc
Provide content across functions to all the BIR countries where we commercialize
Be the voice for these therapeutic areas for BIR, including to BIR LT, Countries and Global
Ensure high competitiveness and strong CI timely for strategic decisions
Represent the BIR to Global teams ensuring that decisions with potential impact on the business have early BIR input (LCM initiatives)
Provide governance and deliver a consistent business structure across the markets ensuring optimal use of resources (Financial and Headcount)
Lead work with countries to identify and then remove “Roadblocks” to sustained business growth ensuring that affiliate resources are externally facing
Manage all governance and put right measures in place e.g. approval processes around EAP, NNP, reversed logistics, etc.
Support key processes like AOP, LRP, ICP together with regional team and the countries
Launch Planning: setting up ELOT (Early Launch Operations Team) and active involvement in EAP planning / execution
The increasing complexity of the BIR business landscape, diversification into new therapeutic areas and the importance of operating a successful leveraged business model with excellent global/regional/local interaction means that the scope and impact of the New Portfolio Lead role requires dedicated oversight. This leader will also need to be cognizant of key differences across geographies and be able to manage a geographically dispersed team and work effectively across a matrixed organization.
/6 years’ experience in cross functional general management role with P&L/
B.A./B.Sc. in related field required (e.g., business, science, technology); M.B.A. preferred.
/Proven success in launches/
/ Strong track record in P&L management/
/ Proven track record in leading in the matrix/
All your information will be kept confidential according to EEO guidelines.